Header Logo

Connection

Nomathemba Chandiwana to Lamivudine

Back to Details
This is a "connection" page, showing publications Nomathemba Chandiwana has written about Lamivudine.
Nomathemba Chandiwana
Connection Strength
0,163
Lamivudine
  1. DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy. HIV Med. 2025 Jan; 26(1):81-96.
    View in: PubMed
    Score: 0,057
  2. Regional variation in weight change after the transition to dolutegravir in Uganda and South Africa. AIDS. 2024 07 15; 38(9):1314-1322.
    View in: PubMed
    Score: 0,055
  3. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG. Clin Infect Dis. 2023 04 17; 76(8):1492-1495.
    View in: PubMed
    Score: 0,052
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.